Figure S2. Results of network meta-analysis of the clinical efficacy of ten GLP-1RAs. Data in each cell are hazard or odds ratios (95% credible intervals) for the comparison of row-defining treatment versus column-defining treatment. Significant results are marked *. Sema=Semaglutide; Dula= Dulaglutide; Exe= Exenatide.

Sema2.0mg										
-0.20* (-0.78,0.38)	Sema1.0mg									
-0.73 (-1.56,0.10)	-0.53 (-1.13,0.07)	Dula4.5mg								
-0.64 (-1.78,0.50)	-0.44 (-1.42,0.55)	0.09 (-0.97,1.15)	Exe2.0mg							
-0.84 (-1.54,-0.15)	-0.64* (-1.04,-0.25)	-0.11 (-0.73,0.50)	-0.21 (-1.23,0.82)	Sema0.5mg						
-0.97 (-1.79,-0.14)	-0.77 (-1.35,-0.18)	-0.23 (-0.65,0.18)	-0.33 (-1.38,0.73)	-0.12* (-0.73,0.49)	Dula3.0mg					
-1.00* (-1.71,-0.29)	-0.80 (-1.22,-0.39)	-0.27 (-0.70,0.16)	-0.36 (-1.35,0.62)	-0.16* (-0.60,0.28)	-0.04 (-0.46,0.38)	Dula1.5mg				
-1.26* (-1.99,-0.54)	-1.06 (-1.50,-0.63)	-0.53 (-1.06,-0.01)	-0.63 (-1.64,0.39)	-0.42* (-0.87,0.04)	-0.30 (-0.82,0.22)	-0.26 (-0.58,0.05)	Dula0.75mg			
-1.55* (-2.52,-0.59)	-1.35 (-2.13,-0.58)	-0.82 (-1.70,0.06)	-0.92 (-1.95,0.12)	-0.71* (-1.54,0.12)	-0.59 (-1.46,0.28)	-0.55 (-1.33,0.23)	-0.29 (-1.11,0.53)	PEX168200ug		
-1.64* (-2.61,-0.68)	-1.44 (-2.22,-0.67)	-0.91 (-1.79,-0.04)	-1.01 (-2.04,0.03)	-0.80* (-1.63,0.03)	-0.68 (-1.55,0.19)	-0.64 (-1.42,0.14)	-0.38 (-1.20,0.44)	-0.09 (-0.66,0.48)	PEX168100ug	
-2.71* (-3.46,-1.96)	-2.51* (-3.00,-2.02)	-1.98* (-2.58,-1.38)	-2.07* (-2.93,-1.22)	-1.87* (-2.43,-1.30)	-1.75* (-2.33,-1.16)	-1.71* (-2.18,-1.24)	-1.45* (-1.98,-0.91)	-1.16* (-1.76,-0.56)	-1.07* (-1.67,-0.46)	Placebo

☐ interventions   ☐ fasting blood glucose